Named as a key player in 297 of our reports, across 33 regions and countries.
2023–2033 CAGR · estimates
| Market | Category | World 2023 | CAGR |
|---|---|---|---|
| Dietary Supplements | OTC & Nutraceuticals | $308 Bn | 6.2% |
| Over The Counter (OTC) Drugs | OTC & Nutraceuticals | $178 Bn | 4.7% |
| Over The Counter (OTC) Pharmaceuticals | OTC & Nutraceuticals | $178 Bn | 4.7% |
| Over The Counter (OTC) Vitamins and Minerals | OTC & Nutraceuticals | $32 Bn | 5.5% |
| Over The Counter (OTC) Analgesics | OTC & Nutraceuticals | $22 Bn | 3.4% |
| Over The Counter (OTC) Medications for Cough, Cold & Flu Drugs | OTC & Nutraceuticals | $14.5 Bn | 4.1% |
| Over The Counter (OTC) Gastrointestinal Drugs | OTC & Nutraceuticals | $5.6 Bn | 3.9% |
| Over The Counter (OTC) Sleep Aid Products | OTC & Nutraceuticals | $5.3 Bn | 4% |
| Anthelmintic Drug | OTC & Nutraceuticals | – | – |
Named as key players in the same markets as GSK PLC (number of shared markets).
Bayer AG6 shared markets
Johnson & Johnson6 shared markets
AstraZeneca5 shared markets
Novartis AG5 shared markets
Pfizer Inc.4 shared markets
Reckitt Benckiser Group PLC4 shared markets
Sanofi S.A4 shared markets
Abbott Laboratories3 shared markets